

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/669,441	09/25/2003	Leland Shapiro	330310.00101

27160
PATENT ADMINSTRATOR
KATTEN MUCHIN ZAVIS ROSENMAN
525 WEST MONROE STREET
SUITE 1600
CHICAGO, IL 60661-3693

CONFIRMATION NO. 4274

FORMALITIES LETTER



OC000000013491472

Date Mailed: 08/10/2004

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.


For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts
Commissioner for Patents

P.O. Box 1450
Alexandria VA 22313-1450

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

Ifu


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent Application of

Leland Shapiro

Application No.: 10/669,441

Filed: September 25, 2003



Attorney Docket No. 330310.00101

Customer No. 27160

Group Art Unit: Unassigned

Examiner: Unassigned

Title: INHIBITORS OF SERINE PROTEASE ACTIVITY METHODS AND COMPOSITIONS FOR TREATMENT OF NITRIC OXIDE-INDUCED CLINICAL CONDITIONS

TRANSMITTAL SHEET FOR SUBMISSION OF SEQUENCE LISTING

Commissioner of Patents
Washington, D.C. 20231

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications

Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated August 10,

2004, please find enclosed:

1. A Response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
2. A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
3. A Sequence Listing;
4. A diskette containing the computerized version of the Sequence Listing; and
5. A postcard.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Serge Sira".

Serge Sira, PH.D.
Registration No. 39,445
Gilberto M. Villacorta, PH.D.
Registration No. 34,038

Dated: September 9, 2004


Patent Administrator

KATTEN MUCHIN ZAVIS ROSENMAN

525 West Monroe Street, Suite 1600

Chicago, Illinois 60661-3693

Facsimile: (312) 902-1061



In re Application of:)
Leland SHAPIRO :
) Attorney Docket No. 330310-00101
Application No.: 10/669,441 :
) Customer No. 27160
Filed: September 25, 2003 :

For: INHIBITORS OF SERINE PROTEASE ACTIVITY METHODS AND COMPOSITIONS FOR TREATMENT
OF NITRIC OXIDE-INDUCED CLINICAL CONDITIONS

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES UNDER 37 C.F.R. §1.821(e), §1.821(f), AND §1.825(b)
AND PRELIMINARY AMENDMENT UNDER 37 C.F.R. §1.115**

Mail Stop: Missing Parts
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:

In response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Under C.F.R. §1.821(e), §1.821(f), and §1.825(b) dated August 10, 2004, please enter the following Preliminary Amendment in the above-identified application and consider the remarks below. Submitted herewith is: (a) Exhibit A, a paper copy of the sequencing listing; and (b) Exhibit B, a computer readable form of the Sequence Listing submitted in accordance with 37 CFR §§ 1.82(c) and (e).